Discover what Anathapindika Health’s AlchePharma retail expansion signals for detox-focused nutraceuticals and the evolving wellness retail landscape.
Tafenoquine’s retail debut via GoodRx marks a shift in malaria prevention access. Find out what this means for U.S. travel medicine strategy.
Explore what Scilex Holding Company’s $20M Quantum Scan investment means for preventive diagnostics and the execution risks ahead.
Arcutis Biotherapeutics takes full control of ZORYVE promotion. See how this shift could affect real-world dermatology and pediatric prescribing.
Find out how Indivior’s move to the United States reshapes governance, regulation, and investor perception in addiction treatment biotech.
Discover why Standard Process’ Cultivate symposium aims to close clinical education gaps in whole-food nutrition and reshape healthy aging care for practitioners.
GenSight Biologics S.A.’s GS010/LUMEVOQ rollout in France and Israel has done more than expand access—it may be redefining how gene therapies are delivered in ophthalmology. As the company prepares for bilateral administration under early access programs for Leber Hereditary Optic Neuropathy (LHON), it is stepping into a growing shift across the field: a move away
The recent U.S. Food and Drug Administration (FDA) approval for RevBio Inc. to begin a pilot trial of its regenerative bone adhesive, TETRANITE, in dental ridge augmentation has reignited industry attention around a long-elusive biomaterials category: viable, clinically integrated bone adhesives. While dental applications are the entry point, the real strategic question is whether these
GenSight Biologics S.A.’s early access rollout of GS010/LUMEVOQ in France and Israel has drawn new attention to how regulators are quietly repurposing compassionate use frameworks into strategic regulatory sandboxes for advanced therapies. As rare disease gene therapies edge closer to commercial viability, a patchwork of early access programs across key jurisdictions is beginning to influence
RevBio Inc. has received approval from the United States Food and Drug Administration to initiate a pilot clinical trial evaluating TETRANITE, its regenerative bone adhesive, for dental ridge augmentation procedures. The trial will examine whether the product can eliminate the need for membranes, meshes, tacks, and fixation screws—elements that have traditionally been considered essential for